{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:50:49Z","timestamp":1784872249139,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.cllc.2023.04.008","type":"journal-article","created":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T09:32:23Z","timestamp":1682242343000},"page":"e205-e213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical Outcomes With Pembrolizumab-Based Therapies in Recurrent\/Refractory NSCLC After Chemoradiation and Consolidative Durvalumab"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6409-2640","authenticated-orcid":false,"given":"Lukas","family":"Delasos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled A.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan A.","family":"Pennell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradnya","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2023.04.008_bib0001","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.cllc.2023.04.008_bib0002","doi-asserted-by":"crossref","unstructured":"Casal-Mouri\u00f1o A, Ruano-Ravina A, Lorenzo-Gonz\u00e1lez M, et\u00a0al. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res [Internet]. 2021;10. Available at: https:\/\/tlcr.amegroups.com\/article\/view\/38800. Accessed: January 5, 2023.","DOI":"10.21037\/tlcr.2020.03.40"},{"key":"10.1016\/j.cllc.2023.04.008_bib0003","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.cllc.2023.04.008_bib0004","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.8511","article-title":"Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: an update from the PACIFIC trial","volume":"39","author":"Spigel","year":"2021","journal-title":"JCO."},{"key":"10.1016\/j.cllc.2023.04.008_bib0005","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jrr\/rrac057","article-title":"Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer","volume":"64","author":"Kishi","year":"2023","journal-title":"J Radiat Res"},{"key":"10.1016\/j.cllc.2023.04.008_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non\u2013small-cell lung cancer","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2023.04.008_bib0007","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non\u2013small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.04.008_bib0008","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2023.04.008_bib0009","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13014-020-01590-8","article-title":"Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer","volume":"15","author":"Taugner","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.cllc.2023.04.008_bib0010","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Guideline Name V.3.2023. National Comprehensive Cancer Network, Inc. 2023. Available at: https:\/\/www.nccn.org\/guidelines\/guidelines-detail. Accessed: January 9, 2023."},{"key":"10.1016\/j.cllc.2023.04.008_bib0011","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.cllc.2023.04.008_bib0012","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.cllc.2023.04.008_bib0013","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"New Engl J Med"},{"key":"10.1016\/j.cllc.2023.04.008_bib0014","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1\u2013selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.cllc.2023.04.008_bib0015","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non\u2013small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.cllc.2023.04.008_bib0016","article-title":"A real-world study on the effectiveness and safety of pembrolizumab plus chemotherapy for nonsquamous NSCLC","volume":"3","author":"Fujimoto","year":"2022","journal-title":"JTO Clin Res Rep [Internet]"},{"key":"10.1016\/j.cllc.2023.04.008_bib0017","article-title":"First-line pembrolizumab monotherapy for advanced NSCLC with programmed death-ligand 1 expression greater than or equal to 50%: Real-world study including older patients in Japan","volume":"3","author":"Goto","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.cllc.2023.04.008_bib0018","article-title":"Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: real-world outcomes at US oncology practices","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.cllc.2023.04.008_bib0019","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1002\/cncr.33142","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non\u2013small cell lung cancer without tumor PD-L1 expression: a pooled analysis of 3 randomized controlled trials","volume":"126","author":"Borghaei","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2023.04.008_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.14046","article-title":"Association between smoking history and overall survival in patients receiving pembrolizumab for first-line treatment of advanced non\u2013small cell lung cancer","volume":"5","author":"Popat","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cllc.2023.04.008_bib0021","article-title":"Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer","author":"Takeuchi","year":"2022","journal-title":"J Cancer Res Clin Oncol [Internet]"},{"key":"10.1016\/j.cllc.2023.04.008_bib0022","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s40425-019-0600-6","article-title":"First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy","volume":"7","author":"Zhou","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"10.1016\/j.cllc.2023.04.008_bib0023","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/1759-7714.14252","article-title":"Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small-cell lung cancer: a multicenter retrospective trial","volume":"13","author":"Matsumoto","year":"2022","journal-title":"Thoracic Cancer"},{"key":"10.1016\/j.cllc.2023.04.008_bib0024","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/annonc\/mdz288","article-title":"Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression","volume":"30","author":"Aguilar","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2023.04.008_bib0025","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/1759-7714.13284","article-title":"Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer","volume":"11","author":"Park","year":"2020","journal-title":"Thoracic Cancer"},{"key":"10.1016\/j.cllc.2023.04.008_bib0026","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lungcan.2022.10.005","article-title":"Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy","volume":"174","author":"Justeau","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2023.04.008_bib0027","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2022.02.014","article-title":"Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations","volume":"167","author":"Riudavets","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2023.04.008_bib0028","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.15589","article-title":"Association of driver oncogene variations with outcomes in patients with locally advanced non\u2013small cell lung cancer treated with chemoradiation and consolidative durvalumab","volume":"5","author":"Liu","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573042300075X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573042300075X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:14:47Z","timestamp":1761506087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152573042300075X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S152573042300075X"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2023.04.008","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes With Pembrolizumab-Based Therapies in Recurrent\/Refractory NSCLC After Chemoradiation and Consolidative Durvalumab","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2023.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}